[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1206335A1 - 具有抗腫瘤活性的色烯酮衍生物 - Google Patents

具有抗腫瘤活性的色烯酮衍生物

Info

Publication number
HK1206335A1
HK1206335A1 HK15106851.8A HK15106851A HK1206335A1 HK 1206335 A1 HK1206335 A1 HK 1206335A1 HK 15106851 A HK15106851 A HK 15106851A HK 1206335 A1 HK1206335 A1 HK 1206335A1
Authority
HK
Hong Kong
Prior art keywords
tumour activity
chromenone derivatives
chromenone
derivatives
tumour
Prior art date
Application number
HK15106851.8A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Sebastien Louis Degorce
Christine Marie Paul Lambert-Van Der Brempt
Remy Robert Morgentin
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1206335A1 publication Critical patent/HK1206335A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15106851.8A 2009-10-27 2015-07-20 具有抗腫瘤活性的色烯酮衍生物 HK1206335A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09306017 2009-10-27

Publications (1)

Publication Number Publication Date
HK1206335A1 true HK1206335A1 (zh) 2016-01-08

Family

ID=43085922

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13100967.4A HK1174027A1 (zh) 2009-10-27 2013-01-22 具有抗腫瘤活性的色烯酮衍生物
HK15106851.8A HK1206335A1 (zh) 2009-10-27 2015-07-20 具有抗腫瘤活性的色烯酮衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13100967.4A HK1174027A1 (zh) 2009-10-27 2013-01-22 具有抗腫瘤活性的色烯酮衍生物

Country Status (42)

Country Link
US (5) US8399460B2 (zh)
EP (1) EP2493870B1 (zh)
JP (2) JP5657010B2 (zh)
KR (1) KR101738195B1 (zh)
CN (2) CN102712615B (zh)
AR (1) AR078786A1 (zh)
AU (1) AU2010311107B9 (zh)
BR (1) BR112012010124B8 (zh)
CA (1) CA2776994C (zh)
CL (1) CL2012001056A1 (zh)
CO (1) CO6541528A2 (zh)
CR (1) CR20120217A (zh)
CU (1) CU20120069A7 (zh)
CY (1) CY1116143T1 (zh)
DK (1) DK2493870T3 (zh)
DO (1) DOP2012000124A (zh)
EA (1) EA020523B9 (zh)
EC (1) ECSP12011838A (zh)
ES (1) ES2530943T3 (zh)
GT (1) GT201200126A (zh)
HK (2) HK1174027A1 (zh)
HN (1) HN2012000889A (zh)
HR (1) HRP20150146T1 (zh)
IL (1) IL219191A0 (zh)
IN (1) IN2012DN03328A (zh)
ME (1) ME02050B (zh)
MX (1) MX2012005027A (zh)
MY (1) MY179833A (zh)
NI (1) NI201200081A (zh)
NZ (1) NZ599457A (zh)
PE (1) PE20130149A1 (zh)
PH (1) PH12012500804A1 (zh)
PL (1) PL2493870T3 (zh)
PT (1) PT2493870E (zh)
RS (1) RS53813B1 (zh)
SA (1) SA110310808B1 (zh)
SI (1) SI2493870T1 (zh)
SM (1) SMT201500036B (zh)
TW (1) TWI483939B (zh)
UA (1) UA107474C2 (zh)
UY (1) UY32978A (zh)
WO (1) WO2011051704A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
UY34013A (es) 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
JP6307096B2 (ja) 2013-01-23 2018-04-04 アストラゼネカ アクチボラグ 化合物
JP6546098B2 (ja) 2013-03-04 2019-07-17 アストラゼネカ アクチボラグ 組み合わせ処置
EP3154960A1 (en) 2014-06-13 2017-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EA201692267A1 (ru) 2014-06-13 2017-06-30 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
ES2750357T3 (es) 2014-06-13 2020-03-25 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa
AU2015274626C1 (en) 2014-06-13 2018-08-09 Gilead Sciences, Inc. Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
KR20170012557A (ko) 2014-06-13 2017-02-02 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
ES2905673T3 (es) * 2015-10-09 2022-04-11 Janssen Pharmaceutica Nv Derivados de quinoxalina y piridopirazina como inhibidores de PI3KBETA
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
KR20210141214A (ko) * 2020-05-15 2021-11-23 제이투에이치바이오텍 (주) 3원환 화합물 및 이의 의약 용도
CA3209581A1 (en) * 2021-02-01 2022-08-04 Geode Therapeutics Inc. Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
MX2023013080A (es) * 2021-05-03 2023-11-16 Petra Pharma Corp Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
EP4334312A1 (en) * 2021-05-03 2024-03-13 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
AU2022282380A1 (en) * 2021-05-27 2023-12-07 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
WO2023104111A1 (en) * 2021-12-08 2023-06-15 Nanjing Zenshine Pharmaceuticals Co., Ltd. Fused heterocyclic compounds as pi3kalpha inhibitors
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
WO2024081904A1 (en) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Methods for treating cancer
WO2025026442A1 (zh) * 2023-08-02 2025-02-06 郑州同源康医药有限公司 稠环类化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027A (en) * 1849-01-09 Rotary blacksmith s twyer
JPH04502322A (ja) 1988-12-21 1992-04-23 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化症性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類
ES2106783T3 (es) 1990-06-20 1997-11-16 Upjohn Co 1-benzopiran-4-onas y 2-amino-1,3-benzoxacin-4-onas antiarterosclerosis y antitromboticas.
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
WO2001053266A1 (en) 2000-01-24 2001-07-26 Kinacia Pty Ltd. Therapeutic morpholino-substituted compounds
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
EP1301498A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
CA2495661C (en) 2002-08-16 2011-06-14 Kinacia Pty Ltd. Inhibition of phosphoinositide 3-kinase beta
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
WO2007045876A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co. Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
CN101506211B (zh) * 2006-04-04 2013-05-22 加利福尼亚大学董事会 激酶拮抗剂
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2112145A1 (en) 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
WO2010134082A1 (en) 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Also Published As

Publication number Publication date
CU20120069A7 (es) 2012-10-15
HN2012000889A (es) 2015-08-03
WO2011051704A1 (en) 2011-05-05
EP2493870B1 (en) 2014-12-17
EA201200618A1 (ru) 2012-12-28
EP2493870A1 (en) 2012-09-05
KR101738195B1 (ko) 2017-05-19
AU2010311107B9 (en) 2014-06-19
CN102712615B (zh) 2014-12-17
US8673906B2 (en) 2014-03-18
NI201200081A (es) 2012-11-07
CO6541528A2 (es) 2012-10-16
SA110310808B1 (ar) 2013-11-24
US20110098271A1 (en) 2011-04-28
GT201200126A (es) 2014-03-03
TW201121960A (en) 2011-07-01
SI2493870T1 (sl) 2015-03-31
EA020523B1 (ru) 2014-11-28
CL2012001056A1 (es) 2012-10-05
CN102712615A (zh) 2012-10-03
SMT201500036B (it) 2015-05-05
PH12012500804A1 (en) 2022-10-03
DK2493870T3 (en) 2015-02-23
JP2013508449A (ja) 2013-03-07
EA020523B9 (ru) 2015-01-30
UA107474C2 (uk) 2015-01-12
BR112012010124A2 (pt) 2016-06-07
DOP2012000124A (es) 2012-07-15
IL219191A0 (en) 2012-06-28
CN104447657B (zh) 2016-08-17
AU2010311107B2 (en) 2014-03-27
JP5657010B2 (ja) 2015-01-21
PE20130149A1 (es) 2013-03-10
MX2012005027A (es) 2012-09-07
MY179833A (en) 2020-11-17
US20130158026A1 (en) 2013-06-20
JP2015078202A (ja) 2015-04-23
CA2776994A1 (en) 2011-05-05
US20160272607A1 (en) 2016-09-22
BR112012010124B8 (pt) 2021-05-25
KR20120098724A (ko) 2012-09-05
AU2010311107A1 (en) 2012-05-03
IN2012DN03328A (zh) 2015-10-23
US9029374B2 (en) 2015-05-12
BR112012010124B1 (pt) 2021-02-17
US20140194419A1 (en) 2014-07-10
HRP20150146T1 (hr) 2015-05-22
NZ599457A (en) 2014-04-30
CA2776994C (en) 2017-10-31
ES2530943T3 (es) 2015-03-09
ECSP12011838A (es) 2012-06-29
CN104447657A (zh) 2015-03-25
US8399460B2 (en) 2013-03-19
US9718800B2 (en) 2017-08-01
RS53813B1 (en) 2015-06-30
CY1116143T1 (el) 2017-02-08
HK1174027A1 (zh) 2013-05-31
US20160060240A1 (en) 2016-03-03
ME02050B (me) 2015-05-20
UY32978A (es) 2011-05-31
PL2493870T3 (pl) 2015-04-30
PT2493870E (pt) 2015-02-18
CR20120217A (es) 2012-06-28
JP5872016B2 (ja) 2016-03-01
AR078786A1 (es) 2011-11-30
TWI483939B (zh) 2015-05-11

Similar Documents

Publication Publication Date Title
HK1206335A1 (zh) 具有抗腫瘤活性的色烯酮衍生物
HUS2300018I1 (hu) Rákellenes hatású kinoli-8-szulfonamid-származékok
HK1173142A1 (zh) -磺酰基- -氟代嘧啶酮衍生物
ZA201203205B (en) Benzimidazole-imidazole derivatives
HK1172893A1 (zh) -氟嘧啶酮衍生物
IL216007A0 (en) Isoxazole-pyridine derivatives
ZA201106855B (en) Oxasiazole derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
PL2484669T3 (pl) Pochodne fenolu
IL214941A0 (en) Isoxazole-pyrazole derivatives
ZA201104991B (en) Deoxyactagardine derivatives
HK1172894A1 (zh) -酰基- -氟嘧啶酮衍生物
HK1169623A1 (zh) 吡嗪並氮雜氧雜環庚烷衍生物
ZA201104279B (en) Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en) Indopyl-pyridone derivatives